白蛋白结合型紫杉醇联合放疗治疗食管癌的临床效果分析  

Analysis of clinical effect of albumin-bound paclitaxel combined with radiotherapy in the treatment of esophageal cancer

作　　者：沙鸥 SHA Ou(Jinxiang County People's Hospital,Second Department of Comprehensive Treatment of Hematological Malignancy,Jinxiang County People's Hospital,Jining 272200,China)

机构地区：[1]金乡县人民医院血液肿瘤综合治疗二科,272200

出　　处：《中国实用医药》2024年第15期15-18,共4页China Practical Medicine

摘　　要：目的观察对食管癌患者实施白蛋白结合型紫杉醇联合放疗治疗的临床效果。方法选取64例食管癌患者,随机分为观察组和对照组,各32例。对照组采取常规紫杉醇新辅助化疗治疗,观察组则实施白蛋白结合型紫杉醇联合放疗进行治疗。比较两组患者治疗效果、不良反应发生率、生活质量及血清肿瘤标志物水平。结果观察组治疗总有效率87.50%高于对照组的59.38%(P<0.05);观察组不良反应发生率15.63%低于对照组的53.13%(P<0.05);观察组社会功能、躯体质量、角色功能、情绪功能评分分别为(90.76±4.35)、(88.25±3.97)、(85.35±3.97)、(83.58±4.68)分,高于对照组的(80.69±4.35)、(78.43±2.75)、(76.12±3.36)、(75.67±4.57)分(P<0.05);观察组血清糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)水平分别为(28.10±1.54)U/ml、(18.97±1.42)U/ml、(1.42±0.15)ng/ml,低于对照组的(29.25±2.06)U/ml、(20.15±2.14)U/ml、(1.74±0.26)ng/ml(P<0.05)。结论对食管癌患者实施白蛋白结合型紫杉醇联合放疗治疗,能够降低患者不良反应的发生率,提升疾病的治疗效果,降低血清肿瘤标志物水平,促进患者生活水平的提升,建议推广。Objective To observe the clinical effect of albumin-bound paclitaxel combined with radiotherapy in the treatment of esophageal cancer.Methods A total of 64 patients with esophageal cancer were randomly divided into an observation group and a control group each with 32 cases.The control group was treated with conventional paclitaxel neoadjuvant chemotherapy,and the observation group was treated with albumin-bound paclitaxel combined with radiotherapy.The therapeutic effect,incidence of adverse reactions,quality of life and serum tumor markers were compared between the two groups.Results The total effective rate of the observation group was 87.50%,which was higher than 59.38%of the control group(P<0.05).The incidence of adverse reactions in the observation group was 15.63%,which was lower than 53.13%in the control group(P<0.05).The scores of social function,body quality,role function and emotional function in the observation group were(90.76±4.35),(88.25±3.97),(85.35±3.97)and(83.58±4.68)points,which were higher than(80.69±4.35),(78.43±2.75),(76.12±3.36)and(75.67±4.57)points in the control group(P<0.05).The serum levels of carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)and carcinoembryonic antigen(CEA)in the observation group were(28.10±1.54)U/ml,(18.97±1.42)U/ml and(1.42±0.15)ng/ml,which were lower than(29.25±2.06)U/ml,(20.15±2.14)U/ml and(1.74±0.26)ng/ml in the control group(P<0.05).Conclusion The implementation of albumin-bound paclitaxel combined with radiotherapy for the treatment of esophageal cancer patients can reduce the incidence of adverse reactions,enhance the therapeutic effect of the disease,reduce the level of serum tumor markers,and promote the improvement of the patients'quality of life,and is recommended to be promoted.

关 键 词：食管癌 白蛋白结合型紫杉醇 放疗 临床效果 

分 类 号：R735.1[医药卫生—肿瘤]